The NEA research team has published its latest paper on the out-of-pocket (OOP) costs of atopic dermatitis (AD) in the U.S. — this time examining OOP costs among caregivers of children with AD compared to adults.
Published On: Jan 14, 2022
Last Updated On: Jan 14, 2022
Today the eczema community is one step closer to having a new treatment option.
Rinvoq® (upadacitinib), by manufacturer AbbVie, has been approved by the U.S. Food and Drug Administration (FDA).
Rinvoq is an oral Janus Kinase (JAK) inhibitor medication for the treatment of refractory, moderate to severe atopic dermatitis (AD) in adults and children 12 years of age and older whose disease is not adequately controlled with other systemic drug products, including biologics, or when use of those therapies are inadvisable. Rinvoq will be available by prescription only.
The inflammation of AD is caused in part by immune system messengers called cytokines that are increased in the blood and the skin. Several of these inflammatory cytokines exert their effects through a chemical signal pathway inside cells known as the JAK-STAT pathway (Janus Kinase-Signal transducer and activators of transcription).
The JAK family has four members – JAK inhibitors can target one or more of these family members to block these immune signals and inhibit the inflammatory effect of key cytokines involved in AD. Rinvoq works by selectively blocking JAK1 resulting in improvement in AD signs and symptoms.
It’s important to talk to your doctor about how atopic dermatitis affects your skin and other aspects of your life. Together, you and your healthcare provider can determine if Rinvoq is an appropriate treatment option.
Visit our New Prescription Treatment hub to learn more about upadacitinib and other new therapies as they are available.